Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Techno DrugsDHA:TECHNODRUG -2.27%37 EBITDA Margin % is 22.66% as of Mar. 2026, which is 25% below its 10-year median of 30.07. GuruFocus rates DHA:TECHNODRUG with a GF Score™ of 37/100. The stock has 10 warning signs investors should review. Among 959 Drug Manufacturers companies, Techno Drugs ranks better than 73.83% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Techno Drugs's EBITDA for the
three
months ended in Mar. 2026 was BDT139 Mil. Techno Drugs's Revenue for the
three
months ended in Mar. 2026 was BDT612 Mil. Therefore, Techno Drugs's EBITDA margin for the quarter that ended in Mar. 2026 was 22.66%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Techno Drugs EBITDA Margin % Related Terms
Techno Drugs EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Techno Drugs's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:TECHNODRUG vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Techno Drugs's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Techno Drugs EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Techno Drugs's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Techno Drugs's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Techno Drugs (DHA:TECHNODRUG) has a EBITDA Margin % of 22.66% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Techno Drugs and its competitors. This is 25% below median its historical median of 30.07. Over the past decade, Techno Drugs' EBITDA Margin % has ranged from 22.27 to 31.99. According to the industry distribution chart, Techno Drugs ranks #251 out of 959 companies in the Drug Manufacturers industry, placing it in the top 26.2%.
Is Techno Drugs' EBITDA Margin % too high?
Techno Drugs' current EBITDA Margin % of 22.66% is 25% below median its 10-year median of 30.07. Over the past 10 years, this metric has ranged from a low of 22.27 to a high of 31.99. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Techno Drugs' value of 22.66% is 81.4% above this industry median. Based on the distribution chart, Techno Drugs ranks #251 out of 959 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Techno Drugs has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Techno Drugs' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Techno Drugs ranks #251 out of 959 companies for EBITDA Margin %. This puts Techno Drugs in the upper half of its industry. The industry median EBITDA Margin % is 12.49. Techno Drugs' value of 22.66% is 81.4% above this benchmark. Historically, Techno Drugs' own EBITDA Margin % has ranged from 22.27 to 31.99 over the past decade. While the company's 10-year median is 30.07 vs. the industry median of 12.49, Techno Drugs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Techno Drugs's current EBITDA Margin % of 22.66% is 81.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Techno Drugs and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Techno Drugs's current EBITDA Margin % is 22.66%, which is 25% below median its own 10-year median of 30.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Techno Drugs stock overvalued right now?
Techno Drugs (DHA:TECHNODRUG) has a current EBITDA Margin % of 22.66%. The current EBITDA Margin % is 22.66%, which is 25% below median its 10-year median of 30.07 and 81.4% above the Drug Manufacturers industry median of 12.49. Techno Drugs' overall GF Score™ is 37/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Techno Drugs (DHA:TECHNODRUG), the current EBITDA Margin % is 22.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Techno Drugs Ltd is a pharmaceutical company. The company manufactures medicines for the healthcare market with quality products, a distribution channel, and doctor-patient acceptance. The company is also engaged in production of Anti-Cancer medicines and medicines for therapeutic areas like oncology, cardiovascular, diabetes, immune suppressor, anesthetics, life-saving antibiotics & contrast media in Bangladesh. The product portfolio of the company include Algicar Plus, Amoclav Forte, Adesol Oral Solution, Aminovet Injection, Apegestrol Tab, Docetex 20 Inj, and others.
37GF Score
Get the complete analysis for DHA:TECHNODRUG
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:TECHNODRUG has been successfully added to your 
